Madrigal Pharmaceuticals Inc (MDGL)
301.66
-6.12
(-1.99%)
USD |
NASDAQ |
Apr 17, 16:00
301.10
-0.56
(-0.19%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.661B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 32.11% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 8.829 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1558 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 82.20% |
Profile
Edit
| Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
| URL | https://www.madrigalpharma.com |
| Investor Relations URL | https://ir.madrigalpharma.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 07, 2025 (est.) |
| Last Earnings Release | Feb. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
| URL | https://www.madrigalpharma.com |
| Investor Relations URL | https://ir.madrigalpharma.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 07, 2025 (est.) |
| Last Earnings Release | Feb. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |